The finding that concentrations of NGAL, TNFR1 and TNFR2 are higher in patients with AKI compared to patients without AKI, in combination with that these biomarkers are increasing with AKI stage, supports the hypothesis that AKI in this population is driven by inflammation. This evidence concerns the gene LCN2 and acute kidney injury.